At what prices were the BCAX option exercise and share sale reported?

The stock options were exercised at $3.7898 per share, and the 41,163 shares of common stock were sold at a weighted average price of $18.8623 per share, with actual sale prices ranging from $18.73 to $18.98 .

Bicara Therapeutics CEO trades 41,163 BCAX shares in Form 4 filing

Q: What insider transaction did BCAX report in this Form 4?

The Chief Executive Officer and director of Bicara Therapeutics Inc. (BCAX) exercised 41,163 stock options and sold 41,163 shares of common stock on 11/24/2025 .

Q: What are the key terms of the BCAX stock option exercised in this Form 4?

The stock option is a right to buy 41,163 shares of common stock at $3.7898 per share, vesting in sixteen equal quarterly installments following August 8, 2023 , and expiring on 08/08/2033 .

Q: What roles does the reporting person hold at Bicara Therapeutics (BCAX)?

The reporting person is identified as both a Director and an Officer , serving as the Chief Executive Officer of Bicara Therapeutics Inc.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Bicara Therapeutics Inc. (BCAX) reported an insider transaction by its Chief Executive Officer, who is also a director. On 11/24/2025, the reporting person exercised stock options for 41,163 shares of common stock at an exercise price of $3.7898 per share and then sold 41,163 shares of common stock at a weighted average price of $18.8623 per share under transaction code "S".

The option exercised is a stock option (right to buy) covering 41,163 shares of common stock, with an exercise price of $3.7898, expiring on 08/08/2033. The filing states that these option shares vest in sixteen equal quarterly installments following August 8, 2023, subject to continued service. After the reported transactions, the reporting person beneficially owns 309,892 shares of common stock and 236,107 stock options, all held directly. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

Insider Trade Summary

Net Seller: 41,163 shares ($776,429)

Net Sell 3 txns

Insider Mazumdar Claire

Role Chief Executive Officer

Sold 41,163 shs ($776K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	41,163	$0.00	--
Exercise	Common Stock	41,163	$3.7898	$156K
Sale	Common Stock	41,163	$18.8623	$776K

Holdings After Transaction: Stock Option (Right to Buy) — 236,107 shares (Direct); Common Stock — 351,055 shares (Direct)

Footnotes (1)

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

11/25/2025 - 06:40 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazumdar Claire

(Last)

(First)

(Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON

02116

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/24/2025		M⁽¹⁾		41,163	A	$3.7898	351,055	D
Common Stock	11/24/2025		S⁽¹⁾		41,163	D	$18.8623⁽²⁾	309,892	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$3.7898	11/24/2025		M⁽¹⁾			41,163	⁽³⁾	08/08/2033	Common Stock	41,163	$0	236,107	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Lara Meisner, Attorney-in-Fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BCAX report in this Form 4?

The Chief Executive Officer and director of Bicara Therapeutics Inc. (BCAX) exercised 41,163 stock options and sold 41,163 shares of common stock on 11/24/2025.

How many BCAX shares and options does the insider own after the transaction?

Following the reported transactions, the insider beneficially owns 309,892 shares of Bicara Therapeutics common stock and 236,107 stock options, all held directly.

Was the BCAX insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

What are the key terms of the BCAX stock option exercised in this Form 4?

The stock option is a right to buy 41,163 shares of common stock at $3.7898 per share, vesting in sixteen equal quarterly installments following August 8, 2023, and expiring on 08/08/2033.

What roles does the reporting person hold at Bicara Therapeutics (BCAX)?

The reporting person is identified as both a Director and an Officer, serving as the Chief Executive Officer of Bicara Therapeutics Inc.